← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT07086482

NCT07086482 Effect of Cyanoacrylate Tissue Adhesive Versus Collagen Sponge on Palatal Donor Site Healing

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07086482
Status Recruiting
Phase EARLY_Phase 1
Sponsor Beirut Arab University
Condition Palate; Wound
Study Type INTERVENTIONAL
Enrollment 22 participants
Start Date 2025-08-04
Primary Completion 2026-03-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cyanoacrylate tissue adhesiveCollagen sponge

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 22 participants in total. It began in 2025-08-04 with a primary completion date of 2026-03-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn if the use of cyanoacrylate glue (PeriAcryl) is effective in healing of the palatal donor site in adults requiring a free gingival graft. The main question\[s\] it aims to answer \[is/are\]: Does PeriAcryl accelerate the palatal tissue healing compared with the use of collagen sponge? Does PeriAcryl usage leave the patients more satisfied? Researcher will compare the outcomes of participants treated with PeriAcryl to those treated with collagen sponge to see if PeriAcryl accelerated the healing process of palatal tissues and led to fewer postoperative complications. Participants will: * be assigned to a study group using PeriAcryl or control group using Collagen sponge. * be followed-up to monitor healing and gather clinical information.

Eligibility Criteria

Inclusion Criteria: * Low-moderate anesthetic risk (ASA I-II) * No restriction on ethnicity or gender * Patients requiring FGG from the palate for periodontal plastic surgery * Clinically healthy gingiva after phase I therapy * Full-mouth plaque index grades 0 and 1 * Bleeding scores \<15% Exclusion Criteria: * Patients who smoke \> 10 cigarettes/day * Patients with coagulation disorders * Systemic diseases * Patients on certain medications that may affect periodontal tissues * Pregnant and lactating patient * Patients with allergies to drugs that will be prescribed during the treatment phase * Pathological mental conditions (dementia, psychosis) and lack of cooperation * Excessive gag reflex

Contact & Investigator

Central Contact

Dania EL Rostom, MSc Oral and Dental Surgery

✉ daniarostom1999@hotmail.com

📞 +96171659355

Principal Investigator

Nayer Aboelsaad

STUDY CHAIR

Professor

Frequently Asked Questions

Who can join the NCT07086482 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Palate; Wound. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07086482 trial and what does that mean for participants?

Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.

Is NCT07086482 currently recruiting?

Yes, NCT07086482 is actively recruiting participants. Contact the research team at daniarostom1999@hotmail.com for enrollment information.

Where is the NCT07086482 trial being conducted?

This trial is being conducted at Beirut, Lebanon.

Who is sponsoring the NCT07086482 clinical trial?

NCT07086482 is sponsored by Beirut Arab University. The principal investigator is Nayer Aboelsaad at Professor. The trial plans to enroll 22 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology